FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells

Toxicology and Applied Pharmacology

Volumn 251, Issue 1, 2011, Pages 8-15

  Fang, Liang ^a   Wang, Huiming ^a   Zhou, Lin ^b   Yu, Da ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Akt; Cisplatin; FOXO3a; Oral squamous cell carcinoma (OSCC); Rapamycin

Indexed keywords

BIM PROTEIN; CISPLATIN; PROTEIN KINASE B; PROTEIN P27; RAPAMYCIN; S PHASE KINASE ASSOCIATED PROTEIN 2; TRANSCRIPTION FACTOR FKHRL1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MOUTH CARCINOMA; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; S-PHASE KINASE-ASSOCIATED PROTEINS; SIROLIMUS; TIME FACTORS; TONGUE NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78751607935     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2010.11.007     Document Type: Article

References (31)

1. Aghi M., Kramm C.M., Chou T.C., Breakefield X.O., Chiocca E.A. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J. Natl Cancer Inst. 1998, 90:370-380.
2. Amornphimoltham P., Patel V., Sodhi A., Nikitakis N.G., Sauk J.J., Sausville E.A., Molinolo A.A., Gutkind J.S. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res. 2005, 65:9953-9961.
3. Amornphimoltham P., Patel V., Leelahavanichkul K., Abraham R.T., Gutkind J.S. A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer. Cancer Res. 2008, 68:1144-1153.
4. Bae-Jump V.L., Zhou C., Boggess J.F., Gehrig P.A. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells. Cancer 2009, 115:3887-3896.
5. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96:857-868.
6. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
7. Dansen T.B., Burgering B.M. Unravelling the tumor-suppressive functions of FOXO proteins. Trends Cell Biol. 2008, 18:421-429.
8. de Mattos S.F., Villalonga P., Clardy J., Lam E.W.F. FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells. Mol. Cancer Ther. 2008, 7:3237-3246.
9. Dijkers P.F., Medema R.H., Lammers J.W.J., Koenderman L., Coffer P.J. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr. Biol. 2000, 10:1201-1204.
10. Dijkers P.F., Medema R.H., Pals C., Banerji L., Thomas N.S., Lam E.W., Burgering B.M., Raaijmakers J.A., Lammers J.W., Koenderman L., Coffer P.J. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol. Cell. Biol. 2000, 20:9138-9148.
11. Dykes D.J., Harrison S.D., Mayo J.G., Griswold D.P. Excision assay for initial evaluation of antitumor drug activity in mice bearing human tumor xenografts. J. Natl Cancer Inst. 1992, 84:528-530.
12. Evan G.I., Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411:342-348.
13. Faivre S., Kroemer G., Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 2006, 5:671-688.
14. Fang L., Hu Q., Hua Z., Li S., Dong W. Growth inhibition of a tongue squamous cell carcinoma cell line (Tca8113) in vitro and in vivo via siRNA-mediated down-regulation of skp2. Int. J. Oral Maxillofac. Surg. 2008, 37:847-852.
15. Fang, L., Wang, H., Zhou, L., Yu, D., in press. Akt-FOXO3a signaling axis dysregulation in human oral squamous cell carcinoma and potent efficacy of FOXO3a-targeted gene therapy. Oral Oncol., doi:10.1016/j.oraloncology.2010.10.010.
16. Gao D.M., Inuzuka H., Tseng A., Chin R.Y., Toker A., Wei W.Y. Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APC-Cdh1-mediated Skp2 destruction. Nat. Cell Biol. 2009, 11:397-U392.
17. Gomez-Gutierrez J.G., Souza V., Hao H.Y., Montes de Oca-Luna R., Dong Y.B., Zhou H.S., McMasters K.M. Adenovirus-mediated gene transfer of FKHRL1 triple mutant efficiently induces apoptosis in melanoma cells. Cancer Biol. Ther. 2006, 5:875-883.
18. Hershko D.D. Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer 2008, 112:1415-1424.
19. Hou G., Zhang Q., Wang L., Liu M., Wang J., Xue L. mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice. Cancer Lett. 2010, 290:248-254.
20. Huang H., Regan K.M., Wang F., Wang D., Smith D.I., van Deursen J.M., Tindall D.J. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc. Natl Acad. Sci. USA 2005, 102:1649-1654.
21. Lin H.K., Wang G.C., Chen Z.B., Teruya-Feldstein J., Liu Y., Chan C.H., Yang W.L., Erdjument-Bromage H., Nakayama K.I., Nimer S., Tempst P., Pandolfi P.P. Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat. Cell Biol. 2009, 11:420-U144.
22. Lu M., Ma J., Xue W., Cheng C., Wang Y., Zhao Y., Ke Q., Liu H., Liu Y., Li P., Cui X., He S., Shen A. The expression and prognosis of FOXO3a and Skp2 in human hepatocellular carcinoma. Pathol. Oncol. Res. 2009, 15:679-687.
23. Luo J., Manning B.D., Cantley L.C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003, 4:257-262.
24. Ma B.B., Lui V.W., Hui E.P., Lau C.P., Ho K., Ng M.H., Cheng S.H., Tsao S.W., Chan A.T. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. Invest New Drugs 2010, 28:413-420.
25. Molinolo A.A., Amornphimoltham P., Squarize C.H., Castilho R.M., Patel V., Gutkind J.S. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol. 2009, 45:324-334.
26. Myatt S.S., Lam E.W. The emerging roles of forkhead box (Fox) proteins in cancer. Nat. Rev. Cancer 2007, 7:847-859.
27. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
28. Reagan-Shaw S., Ahmad N. The role of Forkhead-box Class O (FoxO) transcription factors in cancer: a target for the management of cancer. Toxicol. Appl. Pharmacol. 2007, 224:360-368.
29. Shapira M., Kakiashvili E., Rosenberg T., Hershko D.D. The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells. Breast Cancer Res. 2006, 8:R46.
30. Tomayko M.M., Reynolds C.P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 1989, 24:148-154.
31. Yang J.Y., Hung M.C. A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin. Cancer Res. 2009, 15:752-757.